Stanford

Emily Egeler

Clinical Trials Regulatory Manager, Cancer Cell Therapy Center

Bio

CURRENT ROLE AT STANFORD

Director, CCT Regulatory Operations and Procedures (CROP)

EDUCATION AND CERTIFICATIONS

- B.A., Northwestern University , Chemistry; Biological Sciences (2004)
- PhD, Stanford University , Chemical & Systems Biology (2012)

LINKS

- SPARK Program website: http://sparkmed.stanford.edu

Publications

PUBLICATIONS

- **Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium.** *Blood advances*

  Stefanski, H., Eaton, A., Baggott, C., Rossoff, J., Verneris, M. R., Keating, A. K., Prabhu, S., Pacenta, H. L., Phillips, C. L., Talano, J., Moskop, A., Margossian, S. P., Myers, et al

  2022

- **MAJOR TUMOR REGRESSIONS IN H3K27M-MUTATED DIFFUSE MIDLINE GLIOMA (DMG) FOLLOWING SEQUENTIAL INTRAVENOUS (IV) AND INTRACEREBROVENTRICULAR (ICV) DELIVERY OF GD2-CAR T-CELLS**

  Monje, M., Majzner, R., Mahdi, J., Ramakrishna, S., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Barsan, V., Richards, R., Campen, C., Reschke, A., Toland, et al

  OXFORD UNIV PRESS INC.2022: 20-21

- **GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas.** *Nature*

  Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., Geraghty, A. C., Good, Z., Mochizuki, et al

  2022

- **Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*

  Schultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, et al

  2021: JCO2003585

- **CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy**

  Frank, M. J., Baird, J. H., Patel, S., Craig, J., Spiegel, J. Y., Ehlinger, Z., Chinnasamy, H., Younes, S. F., Oak, J. S., Natkunam, Y., Reynolds, W. D., Iglesias, M., Crawford, et al

  AMER SOC HEMATOLOGY.2021

- **Tisagenlecleucel Outcomes in Relapsed/Refractory Extramedullary ALL: A Pediatric Real World CAR Consortium Report.** *Blood advances*
  Fabrizio, V. A., Phillips, C. L., Lane, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H. L., Rossoff, J., Stefanski, H., Talano, J. A., Moskop, A., Margossian, et al
  2021

- **Optimal fludarabine lymphodepletion is associated with improved outcomes following CAR T-cell Therapy.** *Blood advances*
  Fabrizio, V. A., Boelens, J. J., Mauguen, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H., Talano, J. A., Moskop, et al
  2021

- **GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas.**
  Majzner, R. G., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Toland, A., Baggott, et al
  AMER ASSOC CANCER RESEARCH.2021

- **SINGLE CELL RNA SEQUENCING FROM THE CSF OF SUBJECTS WITH H3K27M+DIPG/DMG TREATED WITH GD2 CAR T-CELLULAR THERAPY**
  Mochizuki, A., Ramakrishna, S., Good, Z., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Toland, A., Baggot, et al
  OXFORD UNIV PRESS INC.2021: 39

- **GD2 CAR T-CELLS MEDIATE CLINICAL ACTIVITY AND MANAGEABLE TOXICITY IN CHILDREN AND YOUNG ADULTS WITH H3K27M-MUTATED DIPG AND SPINAL CORD DMG**
  Majzner, R., Ramakrishna, S., Mochizuki, A., Patel, S., Chinnasamy, H., Yeom, K., Schultz, L., Richards, R., Campen, C., Reschke, A., Mahdi, J., Martin, A., Toland, et al
  OXFORD UNIV PRESS INC.2021: 49-50

- **Discovery and Preclinical Work** *A Practical Guide to Drug Development in Academia - The SPARK Approach*
  edited by Mochly-Rosen, D., Grimes, K.
  Springer.2013; 1: 31–77

- **Intracellular Context Affects Levels of a Chemically Dependent Destabilizing Domain** *PLOS ONE*
  Sellmyer, M. A., Chen, L., Egeler, E. L., Rakhit, R., Wandless, T. J.
  2012; 7 (9)

- **Ligand-switchable Substrates for a Ubiquitin-Proteasome System** *JOURNAL OF BIOLOGICAL CHEMISTRY*
  Egeler, E. L., Urner, L. M., Rakhit, R., Liu, C. W., Wandless, T. J.
  2011; 286 (36): 31328-31336

- **Regulating protein stability in mammalian cells using small molecules.** *Cold Spring Harbor protocols*
  Hagan, E. L., Banaszynski, L. A., Chen, L., Maynard-Smith, L. A., Wandless, T. J.
  2009; 2009 (3): pdb prot5172-?